SG11201900154VA - Compounds, compositions, and methods for the treatment of disease - Google Patents
Compounds, compositions, and methods for the treatment of diseaseInfo
- Publication number
- SG11201900154VA SG11201900154VA SG11201900154VA SG11201900154VA SG11201900154VA SG 11201900154V A SG11201900154V A SG 11201900154VA SG 11201900154V A SG11201900154V A SG 11201900154VA SG 11201900154V A SG11201900154V A SG 11201900154VA SG 11201900154V A SG11201900154V A SG 11201900154VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- shrewsbury
- compositions
- compounds
- rule
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662363123P | 2016-07-15 | 2016-07-15 | |
| US201662411405P | 2016-10-21 | 2016-10-21 | |
| PCT/US2017/042106 WO2018013908A1 (en) | 2016-07-15 | 2017-07-14 | Compounds, compositions, and methods for the treatment of disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201900154VA true SG11201900154VA (en) | 2019-02-27 |
Family
ID=60953343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201900154VA SG11201900154VA (en) | 2016-07-15 | 2017-07-14 | Compounds, compositions, and methods for the treatment of disease |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190292215A1 (es) |
| EP (1) | EP3484504A4 (es) |
| JP (1) | JP2019521138A (es) |
| KR (1) | KR20190039522A (es) |
| CN (1) | CN109715202A (es) |
| AU (1) | AU2017295883A1 (es) |
| CA (1) | CA3030830A1 (es) |
| CR (1) | CR20190071A (es) |
| IL (1) | IL264156A (es) |
| MX (1) | MX2019000660A (es) |
| PH (1) | PH12019500095A1 (es) |
| SG (1) | SG11201900154VA (es) |
| WO (1) | WO2018013908A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX363780B (es) | 2015-12-03 | 2019-04-03 | Glaxosmithkline Ip Dev Ltd | Dinucleótidos de purina cíclica como moduladores del estimulador de los genes de interferón. |
| JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
| JP7160833B2 (ja) | 2017-04-13 | 2022-10-25 | サイロパ ビー．ブイ． | 抗ｓｉｒｐアルファ抗体 |
| AR113224A1 (es) | 2017-04-28 | 2020-02-19 | Novartis Ag | Conjugados de anticuerpo que comprenden un agonista de sting |
| CN111566119A (zh) | 2017-11-10 | 2020-08-21 | 武田药品工业有限公司 | Sting调节剂化合物以及制备和使用方法 |
| WO2019123340A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| CA3084582A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| CA3093888A1 (en) | 2018-04-06 | 2019-10-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| US20210170043A1 (en) | 2018-10-31 | 2021-06-10 | Novartis Ag | Dc-sign antibody conjugates comprising sting agonists |
| EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| CA3129011C (en) | 2019-03-07 | 2023-12-19 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| EP3934757B1 (en) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| JP2022538690A (ja) | 2019-07-05 | 2022-09-05 | タンボ・インコーポレイテッド | トランス－シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用 |
| EP4134098A4 (en) | 2020-04-10 | 2024-05-15 | Ono Pharmaceutical Co | CANCER THERAPY METHODS |
| EP4192506A1 (en) | 2020-08-07 | 2023-06-14 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| PE20231947A1 (es) | 2020-11-09 | 2023-12-05 | Takeda Pharmaceuticals Co | Conjugados de anticuerpo y farmaco |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8076303B2 (en) * | 2005-12-13 | 2011-12-13 | Spring Bank Pharmaceuticals, Inc. | Nucleotide and oligonucleotide prodrugs |
| JP5998326B2 (ja) * | 2009-07-06 | 2016-09-28 | ウェイブ ライフ サイエンス リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | 新規核酸プロドラッグおよびその使用方法 |
| EP3524252A1 (en) * | 2010-08-30 | 2019-08-14 | Spring Bank Pharmaceuticals, Inc. | Design of oligonucleotide analogs as therapeutic agents |
| JP6502267B2 (ja) * | 2013-02-18 | 2019-04-17 | スプリング バンク ファーマシューティカルズ，インコーポレイテッド | ワクチンアジュバントおよび治療剤としての短鎖オリゴヌクレオチドの設計 |
| PT3233882T (pt) * | 2014-12-16 | 2020-01-21 | Kayla Therapeutics | Dinucleótidos cíclicos fluorados para a indução de citocinas |
| WO2017011622A1 (en) * | 2015-07-14 | 2017-01-19 | Spring Bank Pharmaceuticals, Inc. | Compounds and compositions that induce rig-i-and other pattern recongnition receptors |
-
2017
- 2017-07-14 KR KR1020197004455A patent/KR20190039522A/ko unknown
- 2017-07-14 CR CR20190071A patent/CR20190071A/es unknown
- 2017-07-14 CA CA3030830A patent/CA3030830A1/en not_active Abandoned
- 2017-07-14 AU AU2017295883A patent/AU2017295883A1/en not_active Abandoned
- 2017-07-14 EP EP17828522.7A patent/EP3484504A4/en not_active Withdrawn
- 2017-07-14 US US16/317,746 patent/US20190292215A1/en not_active Abandoned
- 2017-07-14 SG SG11201900154VA patent/SG11201900154VA/en unknown
- 2017-07-14 CN CN201780050675.9A patent/CN109715202A/zh active Pending
- 2017-07-14 MX MX2019000660A patent/MX2019000660A/es unknown
- 2017-07-14 WO PCT/US2017/042106 patent/WO2018013908A1/en unknown
- 2017-07-14 JP JP2019501573A patent/JP2019521138A/ja active Pending
-
2019
- 2019-01-09 IL IL264156A patent/IL264156A/en unknown
- 2019-01-14 PH PH12019500095A patent/PH12019500095A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3030830A1 (en) | 2018-01-18 |
| EP3484504A1 (en) | 2019-05-22 |
| IL264156A (en) | 2019-02-28 |
| AU2017295883A1 (en) | 2019-02-21 |
| EP3484504A4 (en) | 2020-07-29 |
| CR20190071A (es) | 2019-10-29 |
| JP2019521138A (ja) | 2019-07-25 |
| CN109715202A (zh) | 2019-05-03 |
| KR20190039522A (ko) | 2019-04-12 |
| US20190292215A1 (en) | 2019-09-26 |
| PH12019500095A1 (en) | 2019-10-28 |
| WO2018013908A1 (en) | 2018-01-18 |
| MX2019000660A (es) | 2019-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201900154VA (en) | Compounds, compositions, and methods for the treatment of disease | |
| SG11201811709WA (en) | Compounds, compositions, and methods for the treatment of disease | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201901390TA (en) | Tetracycline compounds and methods of treatment | |
| SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
| SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
| SG11201408054RA (en) | Pegylated oxm variants | |
| SG11201901834WA (en) | Micrornas as biomarkers for endometriosis | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201808476SA (en) | Recycling of polymer matrix composite | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201803676PA (en) | Site specific her2 antibody drug conjugates | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201810143PA (en) | Exon skipping oligomers for muscular dystrophy | |
| SG11201810429UA (en) | Anti-cd19 antibody formulations | |
| SG11201810352XA (en) | New antibacterial compounds | |
| SG11201804589TA (en) | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists | |
| SG11201810078PA (en) | Stabilized pre-fusion rsv f proteins | |
| SG11201807038UA (en) | Rodents having a humanized tmprss gene | |
| SG11201805755SA (en) | Methods of administering hepcidin | |
| SG11201408509PA (en) | Racecadotril lipid compositions | |
| SG11201903154YA (en) | Antibodies that bind zika virus envelope protein and uses thereof | |
| SG11201909107YA (en) | Stenosis treatment |